Patients with PAH | |
Subjects n | 37 |
Sex | |
Male | 17 |
Female | 20 |
Age years | 50±14 |
PAH subtype | |
Idiopathic PAH | 31 (84) |
Heritable PAH | 2 (5) |
PAH associated with | 4 (11) |
HIV infection | 1 |
Connective tissue disease | 3 |
Treatment | |
PDE5i | 16 (43) |
ERA | 22 (59) |
sGC stimulator | 14 (38) |
Prostanoid | 8 (22) |
Selexipag | 3 (8) |
Combination therapy | |
Dual therapy | 10 (27) |
Triple therapy | 9 (24) |
WHO functional class# | |
I | 2 (6) |
II | 17 (47) |
III | 17 (47) |
BNP¶ pg·mL−1 | 66 (26–177) |
DLCO# % predicted | 61 (48–71) |
Right heart catheterisation | |
mPAP mmHg | 38 (34–54) |
RAP mmHg | 6±3 |
PVR Wood units | 6.6 (4.3–10.4) |
Cardiac index L·min−1·m−2 | 2.8±0.7 |
PAWP mmHg | 9±3 |
Data are presented as n (%), mean±sd and median (interquartile range), unless otherwise indicated. PAH: pulmonary arterial hypertension; PDE5i: phosphodiesterase type 5 inhibitor; ERA: endothelin receptor antagonist; sGC: soluble guanylate cyclase; WHO: World Health Organization; BNP: B-type natriuretic peptide; DLCO: diffusion capacity of the lung for carbon monoxide; mPAP: mean pulmonary artery pressure; RAP: right atrial pressure; PVR: pulmonary vascular resistance; PAWP: pulmonary artery wedge pressure. #: n=36; ¶: n=35.